Agilent Technologies Inc. (NYSE: A) announced on March 9, 2026, that it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical and research pathology solutions, from an investor group led by Excellere Partners and GHO Capital Partners LLP. The...
Citi adjusted its ratings and price targets across the life science sector on Wednesday, initiating a 90-day upside catalyst watch for Agilent Technologies while cutting its price target on Icon PLC amid a turbulent earnings season. The firm named Agilent its top tools pick, Natera...
Agilent Technologies Inc. (NYSE: A) has announced a definitive agreement to acquire Biocare Medical in an all-cash transaction valued at $950 million. The deal targets Biocare from an investor group led by Excellere Partners and GHO Capital Partners LLP, marking Agilent's expansion into clinical and...
Agilent Technologies (NYSE: A) shares surged nearly 17% on Thursday following a strong quarterly earnings report released after market close the previous day. The healthcare and medical device specialist reported fiscal second-quarter revenue of $1.83 billion, representing a 10% year-over-year increase. Net income excluding non-GAAP...
Agilent Technologies (NYSE: A) shares surged approximately 17% on Thursday, reaching $135.42, marking the stock's best one-day performance in nearly 24 years following a strong second-quarter fiscal 2026 earnings report that exceeded analyst expectations. The company reported net income of $339 million, or $1.20 per...
Excellere Partners and GHO Capital Partners LLP have announced that Biocare Medical has entered into an agreement to be acquired by Agilent Technologies. The deal marks the end of a ownership period that began in 2021, during which the company achieved annual double-digit revenue and...
Bleakley Financial Group LLC established a new position in Agilent Technologies, Inc. (NYSE:A) during the first quarter, purchasing 16,543 shares valued at approximately $1.89 million. Several other institutional investors, including Fiduciary Trust Co and NorthCrest Asset Management, also increased their holdings in the medical research...
Agilent Technologies (A) reported a strong second quarter, beating revenue, margin, and EPS expectations. The company posted Q2 revenue of $1.83 billion, representing a 10% reported increase driven by core growth of 6.3% and a 3.7% currency tailwind. Non-GAAP operating margins expanded to 26.4%, up...
Snowflake shares surged nearly 37% in premarket trading following first-quarter results that beat analyst expectations, with adjusted earnings of 39 cents per share and revenue of $1.39 billion against estimates of 32 cents and $1.32 billion respectively. The company also announced a significant commitment to...
Agilent Technologies (NYSE:A) has entered into an agreement to acquire privately held Biocare Medical in an all-cash transaction valued at $950 million. The acquisition is designed to strengthen Agilent's position within cancer diagnostics and laboratory technologies, with Biocare set to integrate into Agilent's Life Sciences...
Bessemer Group Inc. reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 37.6% during the first quarter, selling 341,594 shares to hold a remaining position of 566,663 shares valued at approximately $64.59 million. This represents a 0.20% ownership stake in the medical research and scientific...
Agilent Technologies (A) reported strong Q2 2026 revenue growth, beating earnings expectations and raising its full-year outlook. The company is also advancing strategic initiatives including the establishment of a China Innovation Center and the acquisition of Biocare. Following these positive results, Agilent's share price has...
Agilent Technologies has received FDA approval to expand the use of its PD-L1 testing technology to four additional tumor types on its Dako Omnis platform. The newly approved indications include esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction cancers....
Agilent Technologies (NYSE: A) shares have fallen approximately 6.2% since its last earnings report, a decline that contrasts with the S&P 500's performance over the same period. The company reported first-quarter fiscal 2026 earnings of $1.36 per share, which missed the Zacks Consensus Estimate by...
Agilent Technologies (NYSE:A) has received U.S. Food and Drug Administration approval for its PD-L1 IHC 22C3 pharmDx diagnostic test, Code SK006, as a companion diagnostic for esophageal or gastroesophageal junction carcinoma patients who may be eligible for treatment with KEYTRUDA, Merck's (MRK) anti-PD-1 therapy. This...
Agilent Technologies, Inc. reported first quarter fiscal year 2026 revenue of $1.80 billion, representing a year-over-year increase of 6.96%. However, this revenue figure missed analyst expectations by approximately $10.01 million. The company's earnings call transcript, dated February 25, 2026, featured comments from CEO Padraig McDonnell...
Dimensional Fund Advisors LP increased its stake in Agilent Technologies by 9.6% during the first quarter, purchasing an additional 185,223 shares to hold a total of 2,108,764 shares valued at $240.3 million. Other major institutional investors also adjusted their positions, with Massachusetts Financial Services Co....
Institutional investors significantly increased their stakes in Agilent Technologies, Inc. (NYSE:A) during the first quarter of 2026. Chicago Partners Investment Group LLC led the activity by increasing its position by 104.6%, adding 4,904 shares to a total holding of 9,593 shares valued at $1.156 million....
Hsbc Holdings PLC increased its stake in Agilent Technologies, Inc. (NYSE:A) by 2.3% during the fourth quarter, purchasing an additional 16,592 shares to hold a total of 753,669 shares valued at $102.64 million. This represents a 0.27% ownership stake in the medical research company. Several...
Agilent Technologies reported a strong second-quarter fiscal 2026 performance, driven by its 'Ignite' operating system which is now delivering durable benefits across pricing, execution, and margins. The company beat earnings estimates with revenue rising 10% to $1.84 billion and adjusted EPS reaching $1.49, surpassing the...
